Safety and toxicity of biosimilars—EU versus US regulation
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 3
Abstract
Background: As patents for biological drugs begin to expire, the need for scientific guidance on biosimilar drugs grows increasingly important. The European Medicines Agency provided the first guidelines to cover the approval of biosimilars in 2005. On 10 February 2012, the US Food and Drug Administration drafted three guidance documents relevant to approval of biosimilars in the US. Objectives: The EU and US regulatory approaches to biosimilar approval were compared evaluating the potential impact on characterizing the safety profile of a proposed biosimilar product. Methods: Applicable legal documents and guidelines from the EU and US were compared. Three main categories were identified as potentially safety-relevant, namely general regulatory requirements, non-clinical and clinical testing strategies. Results: No fundamental differences were identified between EU and US guidelines concerning the non-clinical and clinical testing strategies. However, extrapolating immunogenicity data from one indication to another is allowed in the US but not in the EU. Further differences were identified in the general regulatory requirements including the reference product, definitions of biological drugs and historic regulatory conditions for distinct product classes. Furthermore, inconsistencies regarding naming and labelling conventions may hamper distinct post-authorization pharmacovigilance measures. Conclusion: Although the regulatory approaches to biosimilar approval in the US and EU are similar in general scientific content, the identified differences might affect the extent of the testing strategy and post-approval pharmacovigilance measures for biosimilars, in particular depending on the type of approval process (generic versus new drug application). In order to ensure globally comparable safety profiles, harmonization of these topics is highly desirable.
Authors and Affiliations
Tobias Blank, Tilo Netzer, Wolfram Hildebrandt, Angela Vogt-Eisele, Marietta Kaszkin-Bettag
Keywords
Related Articles
- EP ID EP354903
- DOI 10.5639/gabij.2013.0203.039
- Views 93
- Downloads 0
Immunogenicity of biosimilar monoclonal antibodies
Biosimilar monoclonal antibodies (mAbs) are making their way onto the drug market. Because these are complex molecules in terms of structure and function, assessing similarity between originator and biosimilar mAb is cha...
Equal protection under the law: Children and the Best Pharmaceuticals for Children Act
Four changes to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act will markedly improve these programmes: expanded attention paid to neonatal studies, support for the off -patent programme,...
Generics substitution in primary care: summary of the Dutch community pharmacies guidelines
Marketed medicines that have passed bioequivalence testing should in general be substitutable. However, for a variety of reasons, caution may be warranted, particularly with regard to narrow therapeutic index drugs and t...
A patient-centred paradigm for the biosimilars market
The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for approval of biosimilar...
New product-specific bioequivalence guidance
For harmonization of the authorization requirements for specific generic applications within the EU, consistent criteria were drafted for 16 active substances, which are out now for public consultation.